Last reviewed · How we verify

Pneumocystosis jiroveci pneumonia — Treatment Landscape & Competitive Intelligence

Pneumocystosis jiroveci pneumonia (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumocystosis jiroveci pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pentam PENTAMIDINE Fresenius Kabi Antiprotozoal Muscarinic acetylcholine receptor M4 1984-01-01
Azo Gantanol SULFAMETHOXAZOLE Pfizer Sulfonamide Antimicrobial [EPC] 1973-01-01
Trimethoprim TRIMETHOPRIM Dr Reddys Labs Sa Sulfonamide Antimicrobial [EPC] Dihydrofolate reductase 1973-01-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
prednisolon prednisolon Hannover Medical School Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Pneumocystosis jiroveci pneumonia
  2. Dr Reddys Labs Sa · 1 drug in Pneumocystosis jiroveci pneumonia
  3. Fresenius Kabi · 1 drug in Pneumocystosis jiroveci pneumonia
  4. Generic (originally Schering) · 1 drug in Pneumocystosis jiroveci pneumonia
  5. Hannover Medical School · 1 drug in Pneumocystosis jiroveci pneumonia
  6. Pfizer · 1 drug in Pneumocystosis jiroveci pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumocystosis jiroveci pneumonia:

Cite this brief

Drug Landscape (2026). Pneumocystosis jiroveci pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumocystosis-jiroveci-pneumonia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing